Gastric mucosa protection in patients treated with iressa and COX-2 inhibitors in malignancies
B Aladics, K Oreskovich, E Schafer, T Gyökeres, J Hamvas, J Moldvay, J Strausz, R Schwab, Á Pap · Zeitschrift für Gastroenterologie · 2004 · Heft 05
Bibliografische Angaben
Zusammenfassung
Background: Gefitinib (ZD1893, Iressa) is an orally active, selective EGFR tyrosine-kinase inhibitor recently approved for the treatment of non-small cell lung cancer (NSCLC) by the FDA. At present, this drug represents one of the most attractive perspectives for the therapy of advanced stage patients especially with brain metastases, who are not eligible for conventional chemotherapy. Also COX-2 inhibitors have been shown to have inhibitory effect on different types of neoplastic conditions including NSCLC. Drugs that cause significant sustained elevation in gastric pH (>5), may reduce plasma concentrations of…
